The 2010 Standards of Medical Care in Diabetes provide guidelines for the management of diabetes, emphasizing the importance of ongoing medical care and patient self-management to prevent complications. These standards aim to guide clinicians, patients, researchers, and payors in diabetes care, with goals and tools to evaluate the quality of care. While individual preferences and comorbidities may require modifications, general targets are provided for most patients. The standards are revised annually and incorporate new evidence. Diabetes is classified into four main types: type 1, type 2, other specific types, and gestational diabetes. Diagnosis is based on plasma glucose criteria, including fasting glucose, 2-hour oral glucose tolerance test (OGTT), and A1C. A1C is now widely accepted for diagnosis, with a threshold of ≥6.5%, and is standardized for accurate results. However, A1C has limitations, such as potential inaccuracies in certain conditions like anemia and hemoglobinopathies. Pre-diabetes, characterized by impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), is a risk factor for future diabetes and cardiovascular disease. Lifestyle interventions, including weight loss and increased physical activity, are effective in preventing or delaying diabetes. Metformin may be considered for high-risk individuals. For asymptomatic patients, testing for diabetes is recommended for those with risk factors, including obesity and other diabetes risk factors. Testing should be done at least every 3 years, with A1C, fasting plasma glucose, or OGTT as appropriate. For children, testing is recommended for those at increased risk, such as those with a family history of diabetes. Gestational diabetes (GDM) is diagnosed using OGTT, with updated criteria from the International Association of Diabetes and Pregnancy Study Groups (IADPSG). Women with GDM should be screened for diabetes postpartum and followed up for future diabetes risk. Prevention and delay of type 2 diabetes involve lifestyle changes and, in some cases, metformin. Glycemic control is crucial, with A1C targets generally set below 7% for most adults. However, individualized goals may be appropriate based on patient factors. Glycemic monitoring, including SMBG and CGM, is essential for managing diabetes, especially for those on insulin therapy. A1C testing is recommended at least twice a year, with more frequent testing for those with changing therapies or unmet glycemic goals. CGM is beneficial for certain populations, particularly those with hypoglycemia unawareness. The standards emphasize the importance of a multidisciplinary approach to diabetes care, with patient education and self-management as integral components. Regular follow-up and adjustments to treatment plans are necessary to achieve optimal glycemic control and prevent complications.The 2010 Standards of Medical Care in Diabetes provide guidelines for the management of diabetes, emphasizing the importance of ongoing medical care and patient self-management to prevent complications. These standards aim to guide clinicians, patients, researchers, and payors in diabetes care, with goals and tools to evaluate the quality of care. While individual preferences and comorbidities may require modifications, general targets are provided for most patients. The standards are revised annually and incorporate new evidence. Diabetes is classified into four main types: type 1, type 2, other specific types, and gestational diabetes. Diagnosis is based on plasma glucose criteria, including fasting glucose, 2-hour oral glucose tolerance test (OGTT), and A1C. A1C is now widely accepted for diagnosis, with a threshold of ≥6.5%, and is standardized for accurate results. However, A1C has limitations, such as potential inaccuracies in certain conditions like anemia and hemoglobinopathies. Pre-diabetes, characterized by impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), is a risk factor for future diabetes and cardiovascular disease. Lifestyle interventions, including weight loss and increased physical activity, are effective in preventing or delaying diabetes. Metformin may be considered for high-risk individuals. For asymptomatic patients, testing for diabetes is recommended for those with risk factors, including obesity and other diabetes risk factors. Testing should be done at least every 3 years, with A1C, fasting plasma glucose, or OGTT as appropriate. For children, testing is recommended for those at increased risk, such as those with a family history of diabetes. Gestational diabetes (GDM) is diagnosed using OGTT, with updated criteria from the International Association of Diabetes and Pregnancy Study Groups (IADPSG). Women with GDM should be screened for diabetes postpartum and followed up for future diabetes risk. Prevention and delay of type 2 diabetes involve lifestyle changes and, in some cases, metformin. Glycemic control is crucial, with A1C targets generally set below 7% for most adults. However, individualized goals may be appropriate based on patient factors. Glycemic monitoring, including SMBG and CGM, is essential for managing diabetes, especially for those on insulin therapy. A1C testing is recommended at least twice a year, with more frequent testing for those with changing therapies or unmet glycemic goals. CGM is beneficial for certain populations, particularly those with hypoglycemia unawareness. The standards emphasize the importance of a multidisciplinary approach to diabetes care, with patient education and self-management as integral components. Regular follow-up and adjustments to treatment plans are necessary to achieve optimal glycemic control and prevent complications.